| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | RAF265 | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | PD-0332991 | CCLE | pan-cancer | AAC | -0.013 | 0.8 |
| mRNA | ML311 | CTRPv2 | pan-cancer | AAC | -0.0089 | 0.8 |
| mRNA | FQI-1 | CTRPv2 | pan-cancer | AAC | 0.013 | 0.8 |
| mRNA | MS-275 | FIMM | pan-cancer | AAC | 0.037 | 0.8 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.012 | 0.8 |
| mRNA | Crizotinib | FIMM | pan-cancer | AAC | -0.048 | 0.8 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | -0.015 | 0.8 |
| mRNA | GSK1059615 | CTRPv2 | pan-cancer | AAC | -0.012 | 0.8 |
| mRNA | salermide | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |